Suggested remit - To appraise the clinical and cost effectiveness of midostaurin within its marketing authorisation for treating advanced systemic mastocytosis
Status In progress
Process STA 2018
ID number 1573

Provisional Schedule

Committee meeting 01 September 2020
Expected publication 11 November 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors Novartis Pharmaceuticals
Others Department of Health and Social Care
  NHS England
  NHS Greater Preston CCG
  NHS Hartlepool and Stockton-on-Tees
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust (ACLT)
  Anthony Nolan
  Black Health Agency
  Cancer Black Care
  Cancer Equality
  Chronic Lymphocytic Leukaemia Support Association
  Chronic Myeloid Leukaemia Support Group
  Genetic Alliance UK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  MPN Voice
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Mastocytosis Support Group
Professional groups Association of Cancer Physicians
  Association of Genetic Nurses and Counsellors
  British Blood Transfusion Society
  British Committee for Standards in
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Gene and Cell
  British Society for Genetic Medicine
  British Society for Haematology
  British Society for Human Genetics
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Chronic Lymphocytic Leukaemia
  UK Clinical Pharmacy Association
  UK Genetic Testing Network
  UK Health Forum
  UK Oncology Nursing Society
  United Kingdom Primary
  Immunodeficiency Network


Associated guideline groups National Guideline Alliance
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord-UK (imatinib)
  Aurobindo Pharma - Milpharm (imatinib)
  Bristol-Myers Squibb Pharmaceuticals (dasatinib)
  Dr. Reddy's Laboratories (imatinib)
  Generics UK (imatinib)
  Intrapharm Laboratories (imatinib)
  Janssen-Cilag (cladribine)
  Lipomed (cladribine)
  Merck Sharp & Dohme (cladribine, interferon alfa-2b)
  Novartis Pharmaceuticals (imatinib, nilotinib)
  Rivopharm UK (imatinib)
  Roche (interferon alfa-2a)
  Sandoz (imatinib)
  Wockhardt UK (imatinib)
Evidence review group Liverpool Reviews and Implementation Group (LRIG)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Blood and Transplant
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Cystic Fibrosis & Genetic
  Disorders Group
  Cochrane Haematological Malignancies
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
18 December 2019 Invitation to participate
18 December 2019 In progress, ITP 18 December 2019
17 May 2019 - 17 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance